Keele Research Repository

Article

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, CE, Emson, M, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, C, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Wilcox, M, Bliss, JM and Yarnold, JR (2020) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 5-year results. Radiotherapy and Oncology, 152 (S1). S346 - S347.

Brunt, AM, Haviland, JS, Sydenham, M, Agrawal, RK, Algurafi, H, Alhasso, A, Barrett-Lee, P, Bliss, P, Bloomfield, D, Bowen, J, Donovan, E, Goodman, A, Harnett, A, Hogg, M, Kumar, S, Passant, H, Quigley, M, Sherwin, L, Stewart, A, Syndikus, I, Tremlett, J, Tsang, Y, Venables, K, Wheatley, D, Bliss, JM and Yarnold, JR (2020) Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. Journal of Clinical Oncology, 38 (28). pp. 3261-3272.

Brunt, AM, Haviland, JS, Wheatley, DA, Sydenham, MA, Alhasso, A, Bloomfield, DJ, Chan, C, Churn, M, Cleator, S, Coles, CE, Goodman, A, Harnett, A, Hopwood, P, Kirby, AM, Kirwan, CC, Morris, C, Nabi, Z, Sawyer, E, Somaiah, N, Stones, L, Syndikus, I, Bliss, JM, Yarnold, JR and FAST-Forward Trial Management Group, . (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395 (10237). 1613 - 1626.

Fernando, IN, Bowden, SJ, Herring, K, Brookes, CL, Ahmed, I, Marshall, A, Grieve, R, Churn, M, Spooner, D, Latief, TN, Agrawal, RK, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Stevens, A, Goodman, A, Canney, P, Bishop, J, Ritchie, D, Dunn, J, Poole, CJ and Rea, DW (2020) Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology, 142. pp. 52-61.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Algurafi, H, Alhasso, A, Bliss, P, Bloomfield, D, Emson, M, Goodman, A, Harnett, A, Passant, H, Tsang, YM, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology*Biology*Physics, 102 (5). 1603 -1604.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Rada, Z, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. British Journal of Cancer, 119 (11). 41 - 41.

Velikova, G, Williams, LJ, Willis, S, Dixon, JM, Loncaster, J, Hatton, M, Clarke, J, Kunkler, IH, Russell, NS, Alhasso, A, Adamson, D, Algurafi, H, Allerton, R, Anandadas, C, Bahl, A, Barraclough, L, Barrett-Lee, P, Barthakur, U, Bedi, C, Beresford, M, Bishop, J, Blackman, G, Bliss, P, Bloomfield, D, Blunt, M, Branson, T, Brazil, L, Brunt, A, Chakrabarti, A, Chittalie, A, Churn, M, Clarke, J, Cleator, S, Crellin, P, Danwata, F, De-Silva-Minor, S, Dhadda, A, Eicholz, A, Fernando, I, Forrest, J, Fraser, J, Geropantas, K, Goodman, A, Grieve, R, Griffin, M, Hadaki, M, Hall, A, Hatton, M, Hicks, J, Hignett, S, Hogg, M, Jyothirmayi, R, Khan, M, Kumar, S, Lawton, P, Lee, D, Lewinski, C, Lim, C, Locke, I, Loncaster, J, Lumsden, G, Lupton, S, Magee, B, Marshall, J, Masinghe, S, McGregor, C, McLennan, M, Memtsa, P, Milanovic, D, Misra, V, Mithal, N, Mukesh, MB, Neal, A, Needleman, S, Persic, M, Quigley, M, Raj, S, Riddle, P, Ritchie, D, Roberts, F, Robson, P, Roe, H, Rolles, M, Shah, N, Sharma, R, Sherwin, E, Simmonds, P, Skailles, G, Skaria, S, Soe, W, Sripadam, R, Stevens, A, Stockdale, A, Storey, N, Storey, N, Syndikus, I, Thorp, N, Thorp, N, Upadhyay, S, Varughese, M, Walji, N, Welch, R, Wells, T, Wolstenholme, V, Wolstenholme, V, Woodings, P and Yuille, F (2018) Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. The Lancet Oncology, 19 (11). 1516 - 1529.

Corrie, PG, Marshall, A, Nathan, PD, Lorigan, P, Gore, M, Tahir, S, Faust, G, Kelly, CG, Marples, M, Danson, SJ, Marshall, E, Houston, SJ, Board, RE, Waterston, AM, Nobes, JP, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Patel, PM, Ottensmeier, CH, Farrugia, D, Humphreys, A, Eccles, B, Young, G, Barker, EO, Harman, C, Weiss, M, Myers, KA, Chhabra, A, Rodwell, SH, Dunn, JA, Middleton, MR, AVAST-M Investigators, Nathan, P, Lorigan, P, Dziewulski, P, Holikova, S, Panwar, U, Tahir, S, Faust, G, Thomas, A, Corrie, P, Sirohi, B, Kelly, C, Middleton, M, Marples, M, Danson, S, Lester, J, Marshall, E, Ajaz, M, Houston, S, Board, R, Eaton, D, Waterston, A, Nobes, J, Loo, S, Gray, G, Stubbings, H, Gore, M, Harries, M, Kumar, S, Goodman, A, Dalgleish, A, Martin-Clavijo, A, Marsden, J, Westwell, S, Casasola, R, Chao, D, Maraveyas, A, Marshall, E, Patel, P, Ottensmeier, C, Farrugia, D, Humphreys, A, Eccles, B, Dega, R, Herbert, C, Price, C, Brunt, M, Scott-Brown, M, Hamilton, J, Hayward, RL, Smyth, J, Woodings, P, Nayak, N, Burrows, L, Wolstenholme, V, Wagstaff, J, Nicolson, M, Wilson, A, Barlow, C, Scrase, C, Podd, T, Gonzalez, M, Stewart, J, Highley, M, Wolstenholme, V, Grumett, S, Goodman, A, Talbot, T, Nathan, K, Coltart, R, Gee, B, Gore, M, Farrugia, D, Martin-Clavijo, A, Marsden, J, Price, C, Farrugia, D, Nathan, K, Coltart, R, Nathan, K and Coltart, R (2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8). 1843 -1852.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Al-hasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Zotova, R, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Radiotherapy and Oncology, 127 (S1). S311 -S312.

Brunt, AM, Wheatley, D, Yarnold, J, Somaiah, N, Kelly, S, Harnett, A, Coles, C, Goodman, A, Bahl, A, Churn, M, Zotova, R, Sydenham, M, Griffin, CL, Morden, JP and Bliss, JM (2016) Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120 (1). pp. 114-118.